logo
  

HNI Corp. Q1 Results Top Estimates

HNI Corp. (HNI) reported Monday that net income attributable to the company for the first quarter surged to $17.7 million or $0.37 per share from $1.6 million or $0.04 per share in the year-ago quarter.

On average, four analysts polled by Thomson Reuters expected the company to report earnings of $0.18 per share for the quarter. Analysts' estimates typically exclude special items.

Net sales for the quarter grew 22.7 percent to $588.0 million from $479.1 million in the same quarter last year. On an organic basis, sales decreased 8.1 percent. The Street was looking for sales of $574.56 million for the quarter.

Looking ahead, the company said adjusted earnings for the second quarter is expected to increase solidly year-over-year driven by the benefit of KII and continued profit transformation in Legacy Workplace Furnishings despite increasingly difficult year-ago comps.

For fiscal 2024, the company expects earnings to increase strongly from 2023 levels driven by continued margin expansion in Workplace Furnishings and the full-year benefit of accretion from KII.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
AbbVie (ABBV) Monday announced a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals, a clinical stage neuroscience biotech firm, to develop next-generation treatment approaches and unmet needs in psychiatric disorders. AbbVie noted that the first-generation compounds may... Healthwest Minerals, Inc. d/b/a Mt. Capra Products has recalled 1,506 boxes of Goat Milk Formula Recipe Kit, also urging consumers to immediately discontinue use of the product as infant formula. The firm does not recommend using this product for infants from 0-12 months of age. Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
RELATED NEWS
Follow RTT